Table 1

Patient characteristics

Women (n = 61)

Men (n = 19)


Age, years

60.8 (57.3 to 64.4)

63.4 (59.8 to 66.9)

Disease duration, yearsa

6.0 (2.0 to 15.0)

5.0 (3.0 to 9.0)

Rheumatoid factor positive, N (%)

51 (84)

14 (74)

Erosive disease, N (%)

47 (77)

14 (74)

ESR, mm/ha

16.0 (9.0 to 29.0)

12.0 (9.0 to 15.0)

C-reactive protein, mg/la

2.0 (1.0 to 8.0)

3.0 (1.0 to 9.0)

DAS28

3.3 (3.0 to 3.6)

2.6 (2.1 to 3.0)

HAQ score (0 to 3)

0.7 (0.5 to 0.8)

0.5 (0.2 to 0.7)

Patients on DMARDs, N (%)

59 (97)

19 (100)

Patients on glucocorticoids, N (%)

17 (28)

3 (16)

Glucocorticoids, dose, mg

4.3 (3.4 to 5.3)

4.2 (0.6 to 7.8)

Hypertension, N (%)

33 (54)

13 (68)

MetS, N (%)

12 (20)

12 (63)


Data is presented as mean (95% confidence intervals) for normally distributed variables and as median (interquartile range) for non-parametric variables.

aMedian.

DAS28, 28-joint Disease Activity Score (where a value of >5.1 is regarded as high disease activity, <3.2 is regarded as low activity and <2.6 is regarded as remission); ESR, erythrocyte sedimentation rate; DMARD, disease-modifying antirheumatic drug (for example, methotrexate, sulfasalazine, hydroxychloroquine, cyclosporine, natriumaurotiomalat and azathioprine); HAQ, Health Assessment Questionnaire; MetS, metabolic syndrome.

Elkan et al. Arthritis Research & Therapy 2009 11:R37   doi:10.1186/ar2643

Open Data